Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

• Published in: American journal of hematology Vol. 99; no. 2; pp. 193 - 202
• Main Authors: Gangat, Naseema, Karrar, Omer, Iftikhar, Moazah, McCullough, Kristen, Johnson, Isla M., Abdelmagid, Maymona, Abdallah, Mostafa, Al‐Kali, Aref, Alkhateeb, Hassan B., Begna, Kebede H., Mangaonkar, Abhishek, Saliba, Antoine N., Hefazi Torghabeh, Mehrdad, Litzow, Mark R., Hogan, William, Shah, Mithun, Patnaik, Mrinal M., Pardanani, Animesh, Badar, Talha, Murthy, Hemant, Foran, James, Palmer, Jeanne, Sproat, Lisa, Khera, Nandita, Arana Yi, Cecilia, Tefferi, Ayalew
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.02.2024; Wiley Subscription Services, Inc
• Subjects: Acute myeloid leukemia; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bridged Bicyclo Compounds, Heterocyclic; Combination therapy; Disease-Free Survival; Genotype; Genotypes; Hematology; Humans; Karyotypes; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Mutation; p53 Protein; Remission; Retrospective Studies; Risk factors; Runx1 protein; Stem cell transplantation; Sulfonamides
• ISSN: 0361-8609; 1096-8652; 1096-8652
• DOI: 10.1002/ajh.27138

Venetoclax + hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our objective in the current retrospective study of 301 adult patients (median age 73 years; 62% de novo) with ND‐AML was to identify molecular predictors of treatment response to Ven‐HMA and survival; European LeukemiaNet (ELN) genetic risk assignment was favorable 15%, intermediate 16%, and adverse 69%. Complete remission, with (CR) or without (CRi), count recovery, was documented in 182 (60%) patients. In multivariable analysis, inclusive of mutations only, “favorable” predictors of CR/CRi were NPM1 (86% vs. 56%), IDH2 (80% vs. 58%), and DDX41 (100% vs. 58%) and “unfavorable” TP53 (40% vs. 67%), FLT3‐ITD (36% vs. 63%), and RUNX1 (44% vs. 64%) mutations; significance was sustained for each mutation after adjustment for age, karyotype, and therapy‐related qualification. CR/CRi rates ranged from 36%, in the presence of unfavorable and absence of favorable mutation, to 91%, in the presence of favorable and absence of unfavorable mutation. At median follow‐up of 8.5 months, 174 deaths and 41 allogeneic stem cell transplants (ASCT) were recorded. In multivariable analysis, risk factors for inferior survival included failure to achieve CR/CRi (HR 3.4, 95% CI 2.5–4.8), adverse karyotype (1.6, 1.1–2.6), TP53 mutation (1.6, 1.0–2.4), and absence of IDH2 mutation (2.2, 1.0–4.7); these risk factors were subsequently applied to construct an HR‐weighted risk model that performed better than the ELN genetic risk model (AIC 1661 vs. 1750): low (n = 130; median survival 28.9 months), intermediate (n = 105; median 9.6 months), and high (n = 66; median 3.1 months; p < .001); survival in each risk category was significantly upgraded by ASCT. The current study identifies genotype signatures for predicting response and proposes a 3‐tiered, CR/CRi‐based, and genetics‐enhanced survival model for AML patients receiving upfront therapy with Ven‐HMA. Overall survival of 301 patients with acute myeloid leukemia receiving frontline venetoclax and hypomethylating agent, (a) stratified by low, intermediate and high risk, and (b) substratified by transplant.